Ascletis Pharma

HKEX: 1672 ↗~$0.5B (HKEX, small-cap) MCAP

Ascletis Pharma is a China-based clinical-stage biopharmaceutical company developing small-molecule and peptide therapeutics for viral diseases, metabolic diseases (including obesity), and oncology. Its lead metabolic candidate ASC36_35 FDC targets GLP-1/GIP agonism.

Company Info

Sector:Therapeutics

Headquarters:Hangzhou, China

Founded:2013

Website:www.ascletis.com/

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting ↗

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting.

Leadership Team

Careers & Job Openings

See all open roles

Multiple Departments

China - Hangzhou

Apply Now →